British artificial intelligence (AI) company BenevolentAI has purchased a drug discovery and development facility located on the Babraham Research Campus in Cambridge, UK, to bolster its AI-enabled development of medicines.
The research facility is expected to enable quicker advancement of BenevolentAI drug programmes into clinic testing at a larger scale. It could further aid in improving the rates of treatment success.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to the firm, the deal will allow it to cover the complete drug development process, from drug discovery to late-stage clinical development.
The facility’s team with expertise in assay development and screening, medicinal and synthetic chemistry, drug metabolism, pharmacokinetics, pharmacology and clinical development is set to work with BenevolentAI’s drug discovery scientists to use AI for accelerating drugs to patients.
BenevolentAI founder and chairman Ken Mulvany said: “We have built an AI technology that can read and understand the world’s biomedical information, then perform complex reasoning, to tell us things about disease never understood before.
“This enables us to discover new medicines like no other organisation and drive cures for diseases that were previously untreatable.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“The acquisition has expanded our scale and capability overnight and created something that previously did not exist – an AI company truly integrated across every stage of the drug discovery process.”
BenevolentAI’s technology is reported have already generated different drug candidates for various complex and previously untreatable diseases. The firm’s drug research pipeline currently includes 19 programmes.
